Clariane (CLARI) AI Stock Analysis

• Market Cap: €1.58B
• Dividend Yield: N/A
• Average Volume (3M): 802.04K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.33
• Revenue Growth: 1.98%
• EPS Growth: 85.87%
• Country: FR
• Employees: 61,798
• Sector: Consumer Goods
• Sector Strength: N/A
• Industry: Medical - Care Facilities
• EPS (TTM): -0.16
• Shares Outstanding: 356,754,460
• 10 Day Avg. Volume: 990,990
• 30 Day Avg. Volume: 802,045
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €4.75
• Price Target Upside: 7.22% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 2

• Rating: 63 Neutral
• Price Target: €4.50 ▲(1.58%Upside)

Korian SA's stock score is mainly influenced by strong financial performance in terms of cash flow and revenue growth, despite challenges in profitability and high leverage. Mixed technical indicators and overvaluation concerns also contribute to a moderate overall score.

Clariane Business Overview & Revenue Model

Company Description

Clariane SE provides a range of medical and non-medical care and support services for the elderly and people with short or longer-term health issues. The company operates long-term care nursing homes, specialized clinics, and assisted living and shared housing facilities for seniors, as well as offers home care, support, and hospitalization services. It operates approximately health care facilities and networks in France, Germany, Italy, Spain, the Netherlands, Belgium, and the United Kingdom. The company was formerly known as Korian and changed its name to Clariane SE in June 2023. Clariane SE was founded in 2001 and is headquartered in Paris, France.

How the Company Makes Money

Clariane makes money primarily through the provision of healthcare services and the sale of wellness products. The company's revenue streams include direct patient care services, subscription-based wellness programs, and partnerships with healthcare providers and institutions. Clariane's earnings are significantly bolstered by its strategic alliances with technology firms, enabling it to offer integrated health solutions that are both effective and scalable. Additionally, the company capitalizes on its brand reputation and extensive distribution networks to drive sales and maintain a competitive edge in the healthcare industry.

Clariane Financial Statement Overview

Summary

Korian SA demonstrates strong operational efficiencies and cash flow management, with consistent revenue growth. However, profitability challenges and high leverage pose potential risks.

Income Statement

Korian SA has shown consistent revenue growth with a compound annual growth rate over the past five years. Despite recent net losses, the company maintains healthy gross and EBIT margins, indicating operational efficiency. The net profit margin remains negative due to the net losses, which impacts overall profitability.

Balance Sheet

The company's balance sheet reflects a high debt-to-equity ratio, suggesting significant leverage, which could pose risks if not managed properly. However, the equity ratio is stable, indicating a sound asset base. Return on equity has been under pressure due to recent net losses, which affects investor returns.

Cash Flow

Korian SA has demonstrated strong cash flow generation capabilities, with rising operating cash flow and positive free cash flow growth. The operating cash flow to net income ratio is robust, highlighting efficient cash flow management. However, the free cash flow to net income ratio is impacted by the net losses.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	5.28B	5.00B	4.44B	4.14B	3.77B
Gross Profit	4.84B	1.57B	4.09B	3.83B	3.48B
EBITDA	1.01B	907.48M	907.45M	841.76M	760.02M
Net Income	-55.12M	-105.25M	22.06M	91.11M	39.40M
Balance Sheet
Total Assets	14.26B	15.18B	14.57B	14.31B	13.20B
Cash, Cash Equivalents and Short-Term Investments	518.10M	677.91M	734.35M	1.22B	1.16B
Total Debt	7.98B	8.55B	8.27B	8.23B	7.71B
Total Liabilities	10.24B	11.24B	10.71B	10.54B	9.87B
Stockholders Equity	3.69B	3.58B	3.54B	3.49B	3.16B
Cash Flow
Free Cash Flow	600.10M	309.05M	116.36M	311.05M	274.67M
Operating Cash Flow	908.13M	804.15M	681.66M	839.97M	794.77M
Investing Cash Flow	47.69M	-669.52M	-770.26M	-825.28M	-1.10B
Financing Cash Flow	-1.11B	-193.61M	-370.09M	31.38M	1.11B

Clariane Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 4.43
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:CLARI, the sentiment is Negative. The current price of 4.43 is below the 20-day moving average (MA) of 4.95, below the 50-day MA of 4.64, and above the 200-day MA of 3.27, indicating a neutral trend. The MACD of -0.05 indicates Positive momentum. The RSI at 39.66 is Neutral, neither overbought nor oversold. The STOCH value of 30.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:CLARI.

Clariane Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CLARI	63 Neutral	€1.58B	―	-1.70%	―	1.98%	85.87%
Sector *	63 Neutral	HK$13.12B	8.62	-8.03%	5.33%	10.83%	-91.29%
0OR2	―	€294.89M	13.26	7.12%	4.71%	―	―
0NEX	―	€2.22B	0.02	-22.82%	―	―	―
0OD6	―	€1.15B	―	-6.74%	―	―	―